MBX Biosciences Names Peter Radovich Independent Director, Sets Board At Eight Seats

The new Class I director gets an option on 18,200 shares and serves until the 2028 annual meeting, the 8-K says.

Share
MBX Biosciences Names Peter Radovich Independent Director, Sets Board At Eight Seats

MBX Biosciences' board appointed Peter Radovich as a director effective Tuesday and set the board's size at eight directors, according to an 8-K filed Thursday. The company is based in Carmel, Indiana.

What the 8-K says

The board acted on a recommendation from its Nominating and Corporate Governance Committee. It determined that Radovich is independent under Nasdaq listing standards.

He is a Class I director and will serve until the 2028 Annual Meeting of Stockholders, under the company's amended and restated by-laws. He continues after that until a successor is elected and qualified, or until his death, removal or resignation.

The filing says there are no arrangements or understandings with any other person under which he was selected. It also says he has no interest in transactions that require disclosure under Item 404(a) of Regulation S-K.

What he gets

As a non-employee director, Radovich receives an initial non-qualified stock option to buy 18,200 shares of common stock. The grant was set for Tuesday, the appointment date.

He also gets cash pay for board service under the company's Non-Employee Director Compensation Policy, as amended in March 2026. The company described that policy in its annual proxy filing, which it filed with the SEC on April 22, 2026.

MBX is also signing an indemnification agreement with him, in the same form it uses with its other directors.

The stock

MBX shares closed at $53.93 at Wednesday's close, up 0.80% for the session. That session ended before the filing was accepted Thursday at 8:11 a.m. ET, so the price does not reflect the news.

The 8-K is signed by President and CEO Steven L. Hoerter and carries no other board changes.

Sources